Reprieve Cardio Nets $42M in Series A Financing

Reprieve Cardiovascular, a company pioneering an intelligent, automated diuretic and fluid management approach for acute decompensated heart failure (ADHF), has raised $42 million in Series A financing.
 
The funding will support the company’s clinical and development programs, including its ongoing FASTR trial and upcoming pivotal trial. The FASTR trial is comparing decongestive therapy administered by the Reprieve decongestion management system to optimal diuretic therapy for ADHF treatment.
 
The Reprieve system aims to personalize decongestion management and safely, quickly, and completely remove excess fluid to improve outcomes and prevent hospital readmissions. It monitoring urine output to deliver tailored diuretic dosing and fluid replacement for ADHF patients.
 
“Today, the standard of care for heart failure patient fluid removal is diuretics. Originally approved 60 years ago, diuretics remain the primary treatment option but can be difficult to administer optimally without real-time patient information,” said Mark Pacyna, CEO of Reprieve. “Reprieve Cardiovascular is bringing intelligent decongestion management to heart failure patients. The Reprieve System provides physicians and care teams added visibility and control throughout treatment.”
 
Pacyna has led Reprieve since May 2021. Prior to that, he spend 16 years with Medtronic, most recently as VP and GM of the company’s Peripheral Vascular business.
 
The funding round was co-led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures.
 
“We’re excited to share the Reprieve story as the company emerges from stealth mode ahead of their pivotal trial,” said Jan Garfinkle, founding and managing partner of Arboretum Ventures. “The series A funding reinforces our belief in the Reprieve team, and in the need for a new technology that can improve the lives of patients suffering from acute decompensated heart failure around the world.”